The Hollister -owned platform will allow NorCal consumers to participate in the virtual global event  Hollister Biosciences Inc. is pleased to announce that its direct-to-consumer delivery platform, Dreamy Delivery, will be the official delivery platform of the 2021 Emerald Cup Awards.  Dreamy Delivery will feature prominently in all Emerald Cup promotions and coverage, and it will help connect Bay Area, ...

The Hollister -owned platform will allow NorCal consumers to participate in the virtual global event

 Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ", " Hollister Cannabis Co. " or " Hollister ") is pleased to announce that its direct-to-consumer delivery platform, Dreamy Delivery, will be the official delivery platform of the 2021 Emerald Cup Awards.  Dreamy Delivery will feature prominently in all Emerald Cup promotions and coverage, and it will help connect Bay Area, Sacramento Hollister and Central Coast consumers with the brands participating in the virtual awards this April.

"The Emerald Cup Awards have been the premier Cannabis Cup in California for 17 years. It is a huge part of the fabric of cannabis in Northern California . We are excited and honored to be the official delivery platform of The Emerald Cup Awards," says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences.

"We're excited to have Dreamy Delivery as our sponsor for this year's Emerald Cup. We share the same values of vetting only the best cannabis products, best business practices, supporting social equity and offering a 5-Star experience. We are honored collaborating together this year." ~Tim Blake, Founder of The Emerald Cup

For the first time in Emerald Cup history, the awards will be a virtual global event streaming on the Social Club TV network. Whether NoCal consumers want to sample the brands taking home the top trophies or try past winners, Dreamy Delivery brings these best-in-class products directly to their front doors utilizing all of the recommended safety protocols. This means virtual participants can experience the 17th-annual event with actual winning products delivered directly and safely to their homes.

As the official delivery platform for the awards, Dreamy Delivery will feature prominently in a six-month promotion that includes social media posts, newsletters, PR statements and brand placement in the title card and afterparty.

The Emerald Cup Awards (described as the "Academy Awards of Cannabis" by Rolling Stone ) celebrate the best emerging and established brands, and a slate of hand-picked judges selects winners that are announced daily during Take Over Week ahead of the official awards celebration. The coverage will culminate in the Social Club TV-broadcasted ceremony on Sunday, April 11, 2021 with the top honors given out in the prestigious cannabis flower categories.

About The Emerald Cup

The Emerald Cup is Northern California's premier cannabis destination. While advancing the concept of sustainable, outdoor farming, its reputation is firmly solidified as the largest, most respected, outdoor cannabis competition in the world. As a group, The Emerald Cup prides itself in bringing together experts and educators in the cannabis industry to our fellow farmers, patients, and patrons each year.

It is a community celebration that has grown to become a global movement honoring the year's finest, organic, sun-grown, cannabis harvest.

https://theemeraldcup.com/

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high-margin model that controls the whole process from manufacture to sales to distribution for what's best described as seed-to-shelf cannabis. Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the first state and locally licensed cannabis company in the city of Hollister, California , birthplace of the "American Biker."

Website: www.hollistercannabisco.co m , https://dreamydelivery.com/

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/dreamy-delivery-announced-as-the-official-delivery-platform-of-the-2021-emerald-cup-awards-301242689.html

SOURCE Hollister Biosciences Inc.

News Provided by PR Newswire via QuoteMedia

Hollister Biosciences CNX:HOLL HSTRF Psychedelics Investing
What Does the FDA Think About Psychedelics?

What Does the FDA Think About Psychedelics?

The development of the psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading authority for drug approvals in the US. This federal body determines whether medical products will ultimately reach the hands of patients.

The FDA reviews the clinical data created by established medical studies evaluating the feasibility of drug compounds or products as treatments for specific ailments.

Keep reading... Show less

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China Taiwan Macau and Hong Kong ) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™.

Keep reading... Show less

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.0 million in gross proceeds.

Keep reading... Show less

Hollister Biosciences Inc. Announces Results of Its 2021 Annual General and Special Shareholder Meeting

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company " or " Hollister Biosciences ") today announced results of its 2021 Annual General and Special Shareholder Meeting (the " Meeting ") held on November 22, 2021 .

Keep reading... Show less

COMPASS Pathways granted fifth US patent for crystalline psilocybin

London, UK - 23 November 2021

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS's 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.

Keep reading... Show less
NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001

NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001

  • FDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss
  • Company plans to file an IND application for a Phase 1/2 clinical study anticipated to start in H1'2022

NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today it successfully completed a pre-Investigational New Drug (IND) consultation with the U.S. Food and Drug Administration (FDA), regarding proposed clinical trials for NeonMind's lead obesity drug candidate, NEO-001. The Company expects to initiate a Phase 12 clinical study in the first half of 2022

"We are extremely pleased with the FDA's feedback and the outcome of the pre-IND consultation, which validated the scientific hypothesis and clinical approach developed by the NeonMind team. The FDA provided helpful feedback and constructive recommendations for the next steps in our development plan. We appreciate the FDA's guidance and are on track to bring the first and only psychedelic-based treatment for obesity into clinical trials," said Robert Tessarolo, President & CEO of NeonMind. "In parallel with an IND submission, we plan to engage with a Contract Research Organization and qualify clinical sites to move expeditiously into a Phase 1/2 Proof-of-Concept study."

Keep reading... Show less

Top News

Related News